ExCulture logo — Fermentation bioprocess technology

ExCulture

Fermentation bioprocess technology

Founded 2022 The Netherlands The Netherlands 4 employees Unknown Total: $350.00K Biotechnology, Pharmaceutical +1

General Information

Company Name ExCulture
Founded Year 2022
Location The Netherlands The Netherlands +1
Employees 4
Industries Biotechnology, Pharmaceutical, Sustainability
Funding Stage Unknown
Social

Get notified when ExCulture moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About ExCulture

ExCulture is an innovative biotech startup that specializes in applying a mixed-culture fermentation bioprocess for the production of pharmaceuticals. Founded in 2022, the company is at the forefront of leveraging advanced biotechnological processes to enhance drug production efficiencies and scalability, addressing a significant need in the pharmaceutical industry.

Despite not having a designated headquarters or specific industry classifications yet, ExCulture has quickly captured the attention of prominent investors. On 01 June 2024, the company secured early venture capital investment from Capricorn Partners and Tech Transfer, indicating strong confidence in its business model and technological potential.

As ExCulture navigates the competitive biotech landscape, its commitment to cutting-edge fermentation techniques makes it a noteworthy contender for investors seeking transformative prospects in the pharmaceutical production domain.

Taxonomy: Mixed-culture fermentation, Pharmaceutical production, Natural fermentation, Life-saving pharmaceuticals, Animal-free bioprocessing, Carbon source optimization, Glycosaminoglycans, Heparin production, Biopharmaceuticals, Innovative fermentation techniques, R&D in bioprocess technology, Sustainable pharmaceutical manufacturing

Services & Products

Development of animal-free heparin substitute
Biopharmaceutical production using mixed culture fermentation

Target Customers

Pharmaceutical companies Healthcare providers Biotech researchers Biopharmaceutical manufacturers

Funding Rounds & Investors (4)

View All
Funding Stage Amount Investors Lead Investors Date
Early VC Unknown 2 Capricorn Partners, Tech transfer 01 Jun 2024
Seed €350.00K 1 01 Dec 2023
Support Program Unknown 1 YES!Delft 01 Dec 2022
Spinout Unknown 2 01 Jan 2022

ExCulture Alternatives & Competitors

ExCulture vs

HEC Group entered the pharmaceutical industry in 2001 by acquiring an API company in Yidu, Hubei, wh...

Post Ipo Equity
120 employees
Pharmaceutical
ExCulture vs
Provenance Bio
Provenance Bio United States

Engineering the future of protein - advancing beauty, nutrition, & tomorrow's materials through prec...

4 employees
ExCulture vs

Sintesi di innovazione, qualità ed eccellenza.

67 employees
Industrial, Manufacturing

FAQ About ExCulture

Fermentation bioprocess technology
ExCulture was founded in 2022.
ExCulture is headquartered in The Netherlands.
ExCulture operates in the following industries: Biotechnology, Pharmaceutical, Sustainability.
ExCulture has approximately 4 employees.
ExCulture has completed 4 funding rounds, raising a total of $350.00K. The latest funding stage is Unknown.
ExCulture offers: Development of animal-free heparin substitute, Biopharmaceutical production using mixed culture fermentation.
Top alternatives and competitors to ExCulture include HEC Pharm Co., Ltd., Provenance Bio, Biosint S.p.A., Nature's Principles, FERMWORX. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
ExCulture and HEC Pharm Co., Ltd. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors ExCulture and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

One analytics cookie (Google Analytics). Cookie Policy